Clinical Director Rare Diseases

george james ltd; United Kingdom; On-site; GBP 100,000 - 130,000; Part time

Benefits offered by this job

Equity/deferred payment during initial phase

Job summary

george james ltd is seeking an experienced Clinical Director for Rare Diseases. The role involves leading the finalisation and execution of a Phase 2 clinical program and requires an MD/PhD with Phase 2 clinical development experience.

Strong regulatory insight (FDA/EMA) is essential, and experience in rare diseases is desirable. The role is initially part-time with potential to move to a full-time position post-funding.

Qualifications

• Experience in Phase 2 clinical development is essential.
• Strong regulatory insight from FDA/EMA is required.
• Experience in rare diseases is desirable.

Responsibilities

• Finalise Phase 2 protocol, endpoints, and regulatory strategy.
• Align clinical documentation to investor- and regulator-ready standard.
• Lead CRO selection and trial readiness.

Skills

Regulatory insight (FDA/EMA)

Phase 2 clinical development

Leadership

Detail-oriented

Education

MD/PhD

Job description

Position: Clinical Director Rare Diseases

Location: UK/Flexible

Reference: JVM200625A

Our client is an award-winning entrepreneurial pharmaceutical company working to drive change in rare diseases. They are seeking an experienced Clinical Director to lead the finalisation and execution of a Phase 2 clinical programme.

The role holder will:

• Finalise Phase 2 protocol, endpoints, and regulatory strategy
• Align clinical documentation to investor- and regulator-ready standard
• Support fundraising and grant applications
• Lead CRO selection and trial readiness

The role demands an MD/PhD with Phase 2 clinical development experience. Strong regulatory insight (FDA/EMA) is required; rare disease expertise is desirable. The role holder must be hands‑on, detail‑oriented, and execution‑focused and comfortable operating in a lean, fast-moving environment.

The role isinitially part-time (equity/deferred payment), moving to paid role post‑funding with potential to scale to full‑time.